PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company’s Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a $6 billion division of the U.S. Department of Health and Human Services (HHS) and system of hospitals providing healthcare to more than two million Native Americans in the United States. Ms. Smith currently serves as Vice Chair at the VENG Group, a non-partisan government relations and public affairs firm where she consults clients on business development, strategy, healthcare and corporate governance.
“We are delighted to welcome Mary to PTC’s Board of Directors,” said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. “Her breadth of knowledge and experience in executive leadership, corporate governance along with her extensive knowledge of the healthcare industry will provide invaluable insights and support as the Company continues to grow.”
Prior to Ms. Smith’s time at the Indian Health Services, she was the Special Counsel & Estate Trust Officer at the Office of Special Deputy Receiver in Chicago, managing and advising on mergers and acquisitions for insurance companies. She has also served as General Counsel at the Illinois Department of Insurance and Counselor in the Civil Division of the U.S. Department of Justice. Ms. Smith holds a law degree from the University of Chicago Law School and earlier in her career, served as the Associate Counsel to the U.S. President in the White House Counsel’s Office. Additionally, Ms. Smith founded the Caroline and Ora Smith Foundation, which sponsors, supports and trains Native American girls in science, technology, engineering and math.
“I am honored to join the PTC Board. PTC’s patient-centered approach to providing relief to people who may have no other options aligns with my dedication to providing health care to underserved populations,” said Mary L. Smith. “I look forward to leveraging my background in highly-regulated environments, corporate governance and public policy to advance PTC’s mission and strategic growth as it continues to expand and progress its impressive pipeline of commercial compounds and compounds in late-stage clinical development across multiple rare diseases.”
About PTC Therapeutics
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company’s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
